ABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform. This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary hyperparathyroidism.
- Mechanism
- Curator reviewed
ABX-PTH is being developed for the treatment of secondary hyperparathyroidism (SHPT). SHPT is a chronic disorder that is frequently observed in patients with chronic kidney disease. Preclinical studies demonstrate ABX-PTH to be highly potent in vivo models of SHPT. ABX-PTH takes a novel approach to addressing secondary hyperparathyroidism (SHPT), because it directly lowers serum levels of free parathyroid hormone.
- Primary indication
- Investigated for use/treatment in chronic renal failure and parathyroid disorders.Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with ABX-PTH, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account